Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI -9.50%12 3-Year EPS without NRI Growth Rate is 57.70% as of Mar. 2026, which is 7113% above its 10-year median of 0.80. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,159 Biotechnology companies, Calidi Biotherapeutics ranks better than 88.87% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 57.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 15.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Calidi Biotherapeutics was 57.70% per year. The lowest was -106.50% per year. And the median was 0.80% per year.
Calidi Biotherapeutics (AMEX:CLDI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Calidi Biotherapeutics 3-Year EPS without NRI Growth Rate Related Terms
CLDI vs BBLG, CDT, BPTH: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's 3-Year EPS without NRI Growth Rate falls into.
Calidi Biotherapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 57.70% mean?
Calidi Biotherapeutics (CLDI) has a 3-Year EPS without NRI Growth Rate of 57.70% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Calidi Biotherapeutics and its competitors. This is 7113% above median its historical median of 0.80. According to the industry distribution chart, Calidi Biotherapeutics ranks #129 out of 1159 companies in the Biotechnology industry, placing it in the top 11.1%.
Is Calidi Biotherapeutics' 3-Year EPS without NRI Growth Rate too high?
Calidi Biotherapeutics' current 3-Year EPS without NRI Growth Rate of 57.70% is 7113% above median its 10-year median of 0.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Calidi Biotherapeutics' value of 57.70% is 256.2% above this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #129 out of 1159 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' 3-Year EPS without NRI Growth Rate compare to BBLG and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #129 out of 1159 companies for 3-Year EPS without NRI Growth Rate. This places Calidi Biotherapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Calidi Biotherapeutics' value of 57.70% is 256.2% above this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 16.20, Calidi Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current 3-Year EPS without NRI Growth Rate of 57.70% is 256.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current 3-Year EPS without NRI Growth Rate is 57.70%, which is 7113% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current 3-Year EPS without NRI Growth Rate of 57.70%. The current 3-Year EPS without NRI Growth Rate is 57.70%, which is 7113% above median its 10-year median of 0.80 and 256.2% above the Biotechnology industry median of 16.20. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current 3-Year EPS without NRI Growth Rate is 57.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
